What Would a Subscription Service Mean for Twitter Stock?

A potential subscription service for Twitter won't ever be that popular, and it's already fully priced into TWTR stock.

Teladoc Stock Is a Victim of the Market, Not a Bad Buy

Teladoc stock has the appearance of a no-brainer contrarian opportunity but investors should carefully look at all arguments.

Buffett, Bezos and Dimon Found Their CEO — Now Comes the Hard Part

It is hoped that by using these three companies as guinea pigs, the lessons learned through Dr. Gawande’s initiative could be rolled out to other Americans, ultimately changing the trajectory of America’s healthcare system for the better.

3 Heart Disease Focused Stocks to Buy Ahead of World Heart Day

With World Heart Day coming up, here is a look at some well-positioned stocks including BioTelemetry (BEAT) in this segment of the market.

National Donuts Day 2017: How to Get Free Donuts at Krispy Kreme, Dunkin’ Donuts and More

National Doughnut Day is June 2, with freebies available at Dunkin Brands Group Inc (DNKN), Krispy Kreme Doughnuts (KKD) and other outlets.

BP Benefits Increased to Cover Autism Therapy, Transgender Surgery and More

BP’s new benefits for U.S. employees include additional parental leave, special therapy for autistic children and gender reassignment surgery.

Same-Scoop Ban: Why Ben & Jerry’s Is Refusing to Sell Two Scoops of the Same Flavor

Ice cream maker Ben & Jerry's is fighting for marriage equality in Australia by banning customers from ordering two scoops of the same flavor.

Inovio Pharmaceuticals Inc (INO) Spikes on HIV Vaccine Trial Results

Inovia Pharmaceuticals Inc (INO) jumped more than 30% its HIV vaccine showed some of the highest overall rates of immune response ever.

Taco Bell (YUM) Again Readies Taco Give-Away for NBA Road-Team Wins

Taco Bell is offering free tacos in the U.S. if the visiting team wins a game during the NBA Finals next month.

The One-Two Punch of Health Tech Stocks

Health tech is an industry that most investors simply can’t afford to ignore, and it's expected to total $3.8 billion by 2018.

Jamba Juice Offering Free Kids Smoothies on July 27

Jamba Juice will be handing out free smoothies to young children this Saturday, July 27 in order to show their commitment to health.

Big Pharma Might Already Have Sights on Abbott Spinoff

Abbott's Humira is a dollar-printing temptation for several companies, but Pfizer's tofacitinib could change the rheumatoid arthritis drug landscape.

Is Abbott’s Spinoff the Beginning of a Trend?

A look at Abbott Labs' (ABT) breakup indicates splitting up may be good medicine for other diversified health care companies.

Pfizer Crafting a Post-Patent Game Plan

As its Lipitor patent nears expiration, Pfizer considers new uses for Lyrica, its popular painkiller for fibromyalgia.

Heed the Red Flags at Amedisys

Congressional scrutiny of home health care specialist Amedisys, along with lowered guidance, are sure-fire signs that investors should proceed with care.

Lilly Should Survive Patent Loss on Blockbuster Drug Zyprexa

On Oct. 23, Eli Lilly will wave goodbye to the U.S. patent on the best-selling drug in its 135-year history. Here's why investors shouldn't be worried.

Onyx’s Staying Power Tied to New Cancer Drug Carfilzomib

Onyx needs the financial boost from its multiple myeloma-treating drug to ween it off dependence on an uneasy partnership with Bayer.

Suit Asks J&J CEO to Return Part of 2010 Pay

J&J CEO Bill Weldon’s gains don’t reflect shareholder pain, some stakeholders say.

Study Results Boost Analyst’s Forecast for Novartis Drug

An analyst boosts his forecast for Novartis' Afinitor based on its promise as a treatment for breast cancer.

FDA’s Easing on Obesity Drugs Could Fatten Investor Wallets

Vivus and Orexigen's diet-pill hopes are resurrected as the FDA relaxes its stance against obesity treatments.